Welcome to Paid Research Studies




  • Condition:   Thyroid Nodule
    Intervention:   Drug: ethanol injection
    Sponsor:   hassan harby mohamed
    Recruiting

  • Conditions:   Acne Vulgaris;   Thyroid Dysfunction
    Intervention:  
    Sponsor:   Assiut University
    Not yet recruiting

  • Condition:   Hypothyroidism
    Intervention:   Drug: Isovue
    Sponsor:   Bracco Diagnostics, Inc
    Recruiting

  • Condition:   Thyroid Nodule
    Intervention:   Diagnostic Test: ultrasound gray-scale ratio
    Sponsor:   First People's Hospital of Hangzhou
    Not yet recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Genetic: •Referral to Genetic Counselor, if indicated
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting

  • Condition:   Thyroid Cancer
    Intervention:   Radiation: I131 1.1 GBq
    Sponsors:   University College, London;   Cancer Research UK
    Recruiting

  • Condition:   Thyroid Neoplasms
    Intervention:   Drug: Lenvatinib
    Sponsor:   Eisai Co., Ltd.
    Recruiting

  • Condition:   Differentiated Thyroid Cancer
    Interventions:   Drug: Cabozantinib;   Drug: Placebo
    Sponsor:   Exelixis
    Recruiting

  • Condition:   Medullary Thyroid Carcer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-Medullary Thyroid Cancer
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Differentiated Thyroid Cancer;   Osteoporosis
    Interventions:   Drug: 99Tc-MDP;   Drug: fosamax;   Drug: Caltrate
    Sponsor:   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    Recruiting

  • Condition:   Differentiated Thyroid Cancer
    Interventions:   Other: NLSCP;   Other: ICT supported HAP
    Sponsor:   National Taiwan University Hospital
    Not yet recruiting

  • Conditions:   Papillary Thyroid Cancer;   Lymph Node Metastases
    Intervention:   Diagnostic Test: OSNA test
    Sponsor:   University of Cagliari
    Recruiting

  • Conditions:   Hurthle Cell Thyroid Cancer;   Tall Cell Variant Thyroid Cancer;   Follicular Thyroid Cancer;   Thyroid Cancer;   Papillary Thyroid Cancer
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Burns;   Liver Fibroses;   Pancreas Disease;   Thyroid Diseases
    Intervention:   Device: Ultrasound/transient elastography
    Sponsor:   The University of Texas Medical Branch, Galveston
    Recruiting

  • Condition:   Thyroid Diseases
    Intervention:   Drug: Prophylactic protocol with Ca and Vit D
    Sponsor:   Hellenic Red Cross Hospital
    Recruiting

  • Condition:   Differentiated Thyroid Carcinoma (DTC)
    Intervention:  
    Sponsor:   Eisai Korea Inc.
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Solid Tumor
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

  • Conditions:   Iodine Excess in Pregnancy;   Selenium Excess in Pregnancy;   Iodine Deficiency in Pregnancy;   Selenium Deficiency in Pregnancy
    Intervention:   Other: Not applicable (for observational studies)
    Sponsor:   Rongrong Li
    Not yet recruiting

  • Conditions:   Hyperthyroidism;   Hypothyroidism
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Medullary Thyroid Cancer;   Infantile Myofibromatosis;   Infantile Fibrosarcoma;   Papillary Thyroid Cancer;   Soft Tissue Sarcoma
    Intervention:   Drug: LOXO-292
    Sponsor:   Loxo Oncology, Inc.
    Recruiting

  • Condition:   Hypothyroidism
    Interventions:   Drug: Iohexol;   Drug: Iodixanol;   Drug: Iopromide
    Sponsors:   GE Healthcare;   Bayer;   Duke Clinical Research Institute
    Not yet recruiting

  • Condition:   Allan-Herndon-Dudley Syndrome
    Intervention:   Drug: Triac
    Sponsor:   Erasmus Medical Center
    Not yet recruiting

  • Condition:   Hyperthyroid
    Intervention:   Behavioral: Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
    Sponsor:   University Hospital, Angers
    Recruiting

  • Conditions:   Endocrine Tumors;   Thyroid Neoplasms;   Parathyroid Neoplasms;   Adrenal Neoplasm;   Neuroblastoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Melanoma and Other Malignant Neoplasms of Skin
    Interventions:   Drug: Cyclophosphamide;   Drug: Etoposide;   Procedure: NK Cell Infusion;   Drug: Mesna
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Malignant Neoplasm of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasm of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Melanoma and Other Malignant Neoplasms of Skin
    Intervention:   Drug: Gemcitabine
    Sponsors:   M.D. Anderson Cancer Center;   James B. and Lois R. Archer Charitable Foundation;   Gateway for Cancer Research
    Recruiting

  • Conditions:   Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Breast Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Other Solid Tumors With Evidence of Activating RET Alteration
    Intervention:   Drug: LOXO-292
    Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company
    Available

  • Conditions:   Thyroid Cancer, Medullary;   Carcinoid Tumor;   Pheochromocytoma;   Paraganglioma;   Insulinoma;   Neuroblastoma
    Intervention:   Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
    Sponsor:   British Columbia Cancer Agency
    Available

  • Conditions:   Carcinoma, Non-Small-Cell Lung;   Thyroid Neoplasms;   Sarcoma;   Colorectal Neoplasms;   Salivary Gland Neoplasms;   Biliary Tract Neoplasms;   Brain Neoplasm, Primary;   Melanoma;   Glioblastoma;   Bile Duct Neoplasms;   Astrocytoma;   Head and Neck Squamous Cell Carcinoma;   Pontine Glioma;   Pancreatic Neoplasms;   Ovarian Neoplasms;   Carcinoma, Renal Cell;   Cholangiocarcinoma;   Skin Carcinoma;   Carcinoma, Bronchogenic;   Bronchial Neoplasms;   Lung Neoplasms;   Respiratory Tract Neoplasms;   Thoracic Neoplasms;   Neoplasms, Nerve Tissue;   Nevi and Melanomas;   Intestinal Neoplasms;   Thyroid Cancer;   GIST;   Malignant Peripheral Nerve Sheath Tumors;   Breast Secretory Carcinoma;   Uterine Neoplasms;   Fibrosarcoma;   Infantile Fibrosarcoma;   Congenital Mesoblastic Nephroma;   Central Nervous System Neoplasms
    Intervention:   Drug: LOXO-195
    Sponsors:   Loxo Oncology, Inc.;   Bayer
    Recruiting

  • Conditions:   Advanced Malignant Neoplasm;   Castleman Disease;   Digestive System Carcinoma;   Erdheim-Chester Disease;   Lip and Oral Cavity Carcinoma;   Lymphangioleiomyomatosis;   Malignant Endocrine Neoplasm;   Malignant Female Reproductive System Neoplasm;   Malignant Male Reproductive System Neoplasm;   Malignant Neoplasm;   Malignant Respiratory Tract Neoplasm;   Malignant Thoracic Neoplasm;   Malignant Urinary System Neoplasm;   Mesothelial Neoplasm;   Metastatic Malignant Neoplasm;   Metastatic Urothelial Carcinoma;   Neurofibromatosis Type 2;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Breast Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Digestive System Carcinoma;   Recurrent Female Reproductive System Carcinoma;   Recurrent Male Reproductive System Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Pharyngeal Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Malignant Neoplasm;   Soft Tissue Neoplasm;   Stage III Breast Cancer AJCC v7;   Stage III Pharyngeal Cancer;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Pharyngeal Cancer;   Stage IVA Pharyngeal Cancer;   Stage IVB Pharyngeal Cancer;   Stage IVC Pharyngeal Cancer;   Thyroid Gland Neoplasm
    Interventions:   Biological: Bevacizumab;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Temsirolimus;   Drug: Valproic Acid
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pheochromocytoma;   Paraganglioma;   Inherited Cancer Syndrome;   Associated Conditions;   Kidney Neoplasms;   Bone Cancer;   Thyroid Neoplasms;   Other Cancer
    Intervention:   Genetic: Genetic screening
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Recruiting

  • Conditions:   Cancer, All Types;   Cancer of Liver;   Cancer of Stomach;   Cancer of Head and Neck;   Cancer of Rectum;   Cancer of Kidney;   Cancer of Esophagus;   Cancer of Colon;   Cancer Skin;   Cancer of Cervix;   Cancer, Metastatic;   Cancer of Larynx;   Cancer of Neck;   Cancer of Lung;   Cancer of Brain and Nervous System;   Cancer of Vulva, Disseminated;   Cancer of Pancreas;   Sarcoma;   GIST;   Small-cell Lung Cancer;   Adenocarcinoma Lung;   Cancer of Prostate;   Cancer, Advanced;   Adrenal Cancer;   Testicular Cancer;   Uterine Cancer;   Bronchoalveolar Cell Lung Cancer;   Cancer Unknown Primary;   Glioblastoma Multiforme;   Oligodendroglioma;   Breast Cancer;   Renal Cell Carcinoma;   Hepatocellular Carcinoma;   Cholangiocarcinoma;   Squamous Cell Carcinoma;   Transitional Cell Carcinoma;   Cancer, Other;   Cancer, Anal;   Melanoma;   Cancer, Bile Duct;   Cancer, Bladder;   Cancer Cords Vocal;   Cancers Cell Neuroendocrine;   Cancer Differentiated Poorly;   Cancer, Anaplastic Thyroid
    Intervention:  
    Sponsors:   SpeciCare;   Dana-Farber Cancer Institute;   Kalispell Regional Medical Center;   Georgia Institute of Technology;   Ontario Institute for Cancer Research;   SEngine Precision Medicine;   Helomics
    Recruiting

  • Conditions:   Kidney Medullary Carcinoma;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Drug: Doxorubicin;   Drug: Gemcitabine;   Drug: Ixazomib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Condition:   Intraoperative Parathyroid Scores System
    Intervention:   Behavioral: with IPSS
    Sponsor:   Fujian Medical University
    Recruiting

  • Conditions:   Pleuropulmonary Blastoma;   Cystic Nephroma;   Ovarian Sertoli-Leydig Cell Tumors;   Ocular Medulloepithelioma;   Nasal Chondromesenchymal Hamartoma
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Autoimmune Encephalitis
    Interventions:   Procedure: Plasma exchange;   Drug: IVIG, High-dose glucocorticoid
    Sponsor:   Yan Zhang
    Recruiting

  • Conditions:   Solid Tumors;   CNS Tumors;   Neuroblastoma
    Intervention:   Drug: Entrectinib
    Sponsor:   Hoffmann-La Roche
    Recruiting

  • Condition:   Solid Tumors Habouring NTRK Fusion
    Intervention:   Drug: BAY2757556 (Larotrectinib, Vitrakvi)
    Sponsor:   Bayer
    Recruiting